Biotech News Alert: Q & A Interview with C.E.O of Sunshine Biopharma (OTCQB: SBFM) Discussing Recent News of Improved Effectiveness of Lead Compound Adva-27a

New York, NY - Point Roberts, WA - April 14, 2014 (Investorideas.com Biotech Newswire) Investorideas.com, a global news source covering leading sectors including biotech and pharma, issues an exclusive Q&A interview with the CEO of Sunshine Biopharma Inc. ( OTCQB: SBFM ), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer.

Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma shares insights into recent developments with the company’s lead compound, Adva-27a.
Interview:
Q: Investorideas.com
The company recently announced improved effectiveness of your lead compound Adva-27a. Can you explain to investors what the results were and what that means moving forward?
A: Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma
We resolved the two isomeric forms of our lead anticancer compound, Adva-27a, and as a result the specific activity of the drug candidate has increased 9.5-fold. We had previously announced that the concentration at which Adva-27a inhibited 50% of the activity of Topoisomerase II, an enzyme that cancer cells use to proliferate, (IC50) was 13.7 micromolar (see press release issued on October 5, 2011). As a result of this recent laboratory development Adva-27a’s IC50 has dropped 9.5-fold, to 1.44 micromolar.
This implies that significantly lower quantities of the drug can be used to achieve the same effect. In the long run, this could also mean lower therapeutic dosages for our future breast cancer and pancreatic cancer patients, which theoretically should result in reduced side-effects.
Q: Investorideas.com
Will this improved effectiveness apply to all the cancers you are targeting or just one specific target?
A: Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma
Yes, theoretically this improved effectiveness applies to all cancer types in which Adva-27a is effective.
Q: Investorideas.com
What triggered you toresolve the two isomeric forms of your lead anticancer compound, Adva-27a?.
A: Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma
Resolving the isomeric forms of a lead compound is usually one of the matters addressed at the final stages of drug synthesis. Not all compounds have isomeric forms. Adva-27a happens to be a compound that does, owing to the presence of a carbohydrate moiety which is important for the anticancer activity of the molecule.
Q: Investorideas.com
You announced in late January that the company is now targeting pancreatic cancer as a second indication for Adva-27a, what is the significance of a second indication?
A: Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma
Pancreatic cancer has an extremely poor prognosis. Most pancreatic cancer patients will die within one year of diagnosis. Cancer of the pancreas is the fourth most common cause of cancer-related deaths in the United States. Recently, the Pancreatic Cancer Action Network released a special report entitled, ‘The Alarming Rise of Pancreatic Cancer Deaths in the United States: Why We Need to Stem the Tide Today’. The alarming findings presented in the report included the fact that by the year 2020, and possibly as early as 2015, pancreatic cancer will move from the fourth leading cause of cancer deaths to the second leading cause of cancer deaths in the United States. It is the aggressive nature and lack of effective therapy that lead us to apply Adva-27a for use against pancreatic cancer.
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
About Sunshine Biopharma Inc. ( OTCBB: SBFM )
Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a, which is currently targeted for multidrug resistant cancer.
www.sunshinebiopharma.com
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.
Follow Investorideas.com on Twitter   http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and use our online stock directories to research stocks - waters stocks, renewable energy, tech, mobile, mining stocks and more… http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure - Disclosure: SBFM effective December 3, 2013 news and content publication (one hundred thousand shares of 144 stock per 3 month period for a total of six months) More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894 . Global investors must adhere to regulations of each country.
800-665-0411 -   Source - www.investorideas.com

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Note: U.S. Clinical Progression

SAN DIEGO - April 9, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.

In the coming months, we plan to initiate the first FDA approved study of Hemopurifier® therapy in the United States. Historically, U.S. clinical progression of extracorporeal devices directed toward a single disease indication has been a proven model for value creation.
Our clinical objectives are a bit more ambitious as we aim to navigate Hemopurifier® therapy into both cancer and infectious disease indications. Yes, we plan to file an investigational device exemption (IDE) to treat cancer later this year. We are also investigating Emergency Use Authorization (EUA) opportunities based on our broad-spectrum bioterror and pandemic threat data and have begun to explore Humanitarian Use Device (HUD) pathways for orphan conditions that affect fewer than 4,000 individuals in the U.S. each year.
To support the breadth of our long-term therapeutic vision, we often encounter challenging decisions. As an example, we recently disclosed a clinical relationship with DaVita Clinical Research, which required a lengthy process to establish and thus contributed to delay the initiation of our hepatitis c virus (HCV) feasibility study. However, the resulting relationship transitioned our potential clinical footprint from a single-site institute to an institute with more than 250 clinical sites to support long-term regulatory objectives.
Since crossing the threshold of having the FDA clear our candidate therapy for human studies, our therapeutic focus has been honed toward clinical progression to support future registration of Hemopurifier® therapy in the United States. The protocol of our forthcoming feasibility study calls for the enrollment of ten HCV-infected end-stage renal disease (ESRD) patients who have not received HCV drug therapy for at least 30 days. The protocol includes a control phase which consists of three consecutive standard dialysis treatments during week one followed by the inclusion of our Hemopurifier® for a total of six treatments administered during weeks two and three. The rate of adverse events observed during the Hemopurifier® treatment phase will be compared to the rate experienced during the control phase. Per-treatment changes of viral load will be observed through PCR analysis and we will also quantitate HCV viral copies captured within the Hemopurifier® during each treatment session. Successful completion of the feasibility study will set the stage for us to conduct pivotal efficacy studies required for Hemopurifier® market clearance. The study will also contribute data toward the human safety challenge requirement to advance the Hemopurifier® as a broad-spectrum countermeasure against viral bioterror and pandemic threats, whose lethality do not allow for the administration of clinical efficacy studies. Based on our experience conducting a similar protocol overseas, we are cautiously optimistic.
In closing, it is our sincere hope to reward shareholders whose support never wavered, even in the face of material setbacks and the clinical uncertainty of whether FDA would permit Hemopurifier® studies in the United States. As a result of this support, we have an opportunity to advance our therapeutic platform into a wide-range of life-threatening disease conditions.
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: 2425 quarterly for annual news publishing only starting Feb 26th 2014
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Biotech News Alert: Sunshine Biopharma (OTCQB: SBFM) Increases the Effectiveness of Adva-27a Lead Compound 9.5-Fold Against Breast and Pancreatic Cancer in Vitro

Montreal, Quebec - April 7, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer today announced that it has resolved the two isomeric forms of its lead anticancer compound, Adva-27a, and as a result the specific activity of the drug candidate has increased 9.5-fold. Sunshine Biopharma had previously announced that the concentration at which Adva-27a inhibited 50% of the activity of Topoisomerase II (IC50) was 13.7 micromolar (see press release issued on October 5, 2011). As a result of today's development Adva-27a's IC50 has dropped 9.5-fold, to 1.44 micromolar. This implies that significantly lower quantities of the drug can be used to achieve the same effect.

"Isomeric forms of a compound refer to the fact that the compound has different arrangements of its atoms in space," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "Isomeric forms do not have identical properties. In the case of Adva-27a, the molecule exists in the alpha or beta form. This is a lot like a person's left hand and right hand. While the two hands look identical, they actually are not. They are mirror images of each other but are not superimposable. The fact that they are not superimposable means that they are not identical. Similarly, the alpha and beta forms of Adva-27a are not superimposable. The implications of all of this for our future breast cancer and pancreatic cancer patients are lower therapeutic dosages, which theoretically should result in reduced side-effects."
About Adva-27a
Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935. The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada).
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.aspBC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Biotech News Alert: MANAGEMENT OF SUNSHINE BIOPHARMA (OTCQB: SBFM) ALARMED BY THE RECENT WORLD HEALTH ORGANIZATION REPORT THAT CANCER IS ON THE RISE

Montreal, Quebec, Canada - March 31, 2014 (Investorideas.com Biotech Newswire) Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer has issued a response to the recently released reports by the World Health Organization and the Pancreatic Cancer Action Network.

"We are very pleased with the progress we have made thus far in our efforts to re-domicile the Company in Canada," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "We are anxious to complete the re-domiciling process as we have attendant growth and financing opportunities that we believe are available to us once we have completed this action. This is important for the Company’s business strategy overall and for our Adva-27a anticancer drug candidate as we advance towards clinical trials for multidrug resistant breast cancer and pancreatic cancer."
According to "World Cancer Report 2014" issued in February by the World Health Organization, cancer is on the rise and has become a leading cause of death worldwide, accounting for 8.2 million deaths in 2012. Lung cancer accounted for 1.59 million deaths and breast cancer represented half a million deaths. The report also says that cancer cases are expected to rise significantly, "It is expected that annual cancer cases will rise from 14 million in 2012 to 22 million within the next two decades."
Additionally the Pancreatic Cancer Action Network released a special report entitled "The Alarming Rise of Pancreatic Cancer Deaths in the United States: Why We Need to Stem the Tide Today". The report noted that "T(t)he alarming findings presented in the report include the fact that by the year 2020, and possibly as early as 2015, pancreatic cancer will move from the fourth leading cause of cancer death to the second leading cause of cancer death in the United States."
"We are alarmed and impassioned by these trends to move vigorously ahead with our clinical development of Adva-27a for aggressive forms of cancer," said Dr. Steve N. Slilaty, Chief Executive Officer of Sunshine Biopharma. "The Company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University's Jewish General Hospital in Montreal (Canada)."
Sunshine Biopharma recently reported that it has initiated the construction of mouse xenograft models for pancreatic cancer as part of the plans of positioning Adva-27a for clinical development for pancreatic cancer in parallel with multidrug resistant breast cancer. Adva-27a is Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on August 7, 2012 under U.S. patent number 8,236,935.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: SBFM has renewed effective December 3,2013 with Investorideas for six months of news publication and general public awareness of the company news and technologies and products in the biopharma markets ( one hundred thousand shares of 144 stock per 3 month period for a total of six months ) More disclaimer info: http://www.investorideas.com/About/Disclaimer.aspBC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

TSX Biotech Stocks to Watch (TSX.V: QPT) (TSX:ONC; NASDAQ:ONCY) (TSX.V:IMV) AEZS) (TSX: AEZ).; Innovative Ovarian Cancer Treatments

New York, NY - Point Roberts, WA - March 26, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues a sector snapshot of TSX biotech stocks targeting ovarian cancer as part of their product pipeline. Stocks mentioned include Quest PharmaTech Inc. (TSX.V: QPT), Oncolytics (TSX:ONC; NASDAQ:ONCY) , Immunovaccine, Inc. (TSX.V:IMV) and Aeterna Zentaris Inc. (AEZS) (TSX: AEZ).

There are 17,000 women living with ovarian cancer in Canada. It is estimated that this year in Canada, 2,600 women will be newly diagnosed with ovarian cancer. Ovarian cancer is the 5th most common cancer for women and is the most fatal women's cancer, says Ovarian Cancer Canada.
According to reported statistics, more than 22,000 women are diagnosed with ovarian cancer in the United States annually, and more than 12,000 die each year.
In February news reports said, "As many as one in four hundred women test positive for the BRCA-1 gene, often called the "breast cancer gene."
They have not only a significantly increased risk for breast cancer, but also for ovarian cancer.”
http://www.wlbz2.com/story/news/nation/2014/03/23/6788983/
Leading U.S. biotech stocks have had a massive bull run this year, although recently the sector has had a correction on concerns of valuations. However some of the smaller microcap stocks have not seen the same volatile trading patterns.
For investors looking at TSX biotech stocks and life sciences stocks, a recently released interview in the Life Sciences Report (TSLR) with Roadmap Capital explains the difference in valuations in US and TSX biotech stocks best.
"TLSR: Why invest primarily in Canadian companies? If you were exclusively a resource investor, and looking for deep value as well as growth, this is understandable, but in the life sciences sector, where the goal is huge growth, why limit yourself to Canadian stocks? Is it about tax advantages? National pride?
HC: I should point out that the new fund has made investments in the U.S. already, and will continue to do so. But we are focusing primarily in Canada. Frankly, it's about where we see the best opportunities and risk/reward ratio. There's no shortage of innovation in Canada, but the long, drawn-out bear market that the Canadian tech and healthcare sectors went through for much of the last decade has left many interesting companies valued at levels far below what is available in other countries. To give you an example, we're putting money into a company with a $2.5M pre-money valuation. Comparable companies in the States would be valued in the $30-40M pre-money range currently. And we have invested a small amount of money into a private stem cell company called Hemostemix. It is raising money at a $25M pre-money valuation, when its best public comparables in the U.S. trade at valuations in the $200—400M range. It comes down to where we see the best valuation opportunities and risk/reward for our investors right now. - "
Source : http://www.equities.com/editors-desk/stocks/healthcare/apply-market-savvy-to-bear-market-debris-uncover-biotech-treasures-cleland-and-ireland cPhase 2 biotech tsx ovarian cancer co's
Sector Snapshot : Ovarian Cancer Treatment
Quest PharmaTech Inc.'s ( TSX.V: QPT).lead product, Oregovomab is currently completing a phase II clinical trial in both Italy and the U.S., is used in combination with standard chemotherapy in ovarian cancer patients. It is also being tested in combination with other immunotherapeutic agents for use in treating pancreatic cancer patients.
From a previous interview with Investorideas.com, Madi R. Madiyalakan, Ph.D., Chief Executive Officer, said "Our technology is focused on the immunotherapy of cancer. We utilize tumor directed monoclonal antibodies to activate the specific immunity; however we recognize that successful therapy requires orchestrated combination with chemotherapy, photodynamic therapy and select additional immune modulators or adjuvants. Our lead product, Oregovomab, which is currently completing a phase II clinical trial in both Italy and the U.S., is used in combination with standard chemotherapy in ovarian cancer patients. We are also initiating a clinical trial using Oregovomab in combination with an immuno-adjuvant, Hiltonol® (TLR3 agonist), with standard chemotherapy. Oregovomab is also being tested in combination with other immunotherapeutic agents for use in treating pancreatic cancer patients. Our pipeline also includes proprietary antibodies against other cancer markers, most notably MUC1, PSA and HER2. We expect to advance our MUC1 targeting antibody into the clinic in the coming year. MUC1 expressing cancers include many commonly occurring solid cancers such as breast, pancreatic and lung cancers. "
Six month chart:
Oncolytics (TSX: ONC; NASDAQ:ONCY)
Oncolytics Biotech Inc. is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company’s lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is currently in late stage (Phase III) clinical testing in head and neck cancers. REOLYSIN® has been utilized in nearly thirty clinical trials including translational, Phase I, Phase II (single arm and randomized), and Phase III studies in a broad range of cancer indications. Ovarian cancer : OG-0186H (NCI / GOG Trial) Phase II Intravenous Administration of REOLYSIN® in Combination with Paclitaxel for Patients with Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer US- status is ongoing.
Six month chart:
Immunovaccine, Inc. (TSX.V: IMV)
According to the company's financial report released March 17th, "During 2013, scientists provided compelling evidence that the human immune system could be trained to destroy cancer cells," said Dr Marc Mansour, chief operating officer. "These findings support the idea that immunotherapies have the potential to shift cancer from a life threatening disease to a chronic and manageable condition.
"Several large pharmaceutical companies also announced during the year that vaccines will play an important role in the development of their cancer therapy programs. These industry trends parallel our own approach to the development of therapeutic cancer vaccines. With our planned trials in ovarian cancer, glioblastoma and breast cancer expected to begin this year, IMV is well placed to participate in this rapidly evolving industry."
Highlights of 2013 and First Quarter of 2014

• DPX-Survivac - Positive data from Immunovaccine's completed Phase I study were presented at multiple venues throughout the year, including the 2013 ASCO annual meeting. We believe that these findings represent some of the strongest immune responses against a cancer target seen to date.

Based on these promising data, Canada's NCIC Clinical Trials Group (NCIC) agreed to sponsor and conduct a randomized Phase II study of DPX-Survivac in patients with advanced ovarian cancer. We expect this study to be initiated in 2014 with results available in 2017. Immunovaccine also signed an agreement with the University of Rome for a multicenter Phase II study of DPX-Survivac in glioblastoma patients. The study is expected to begin in 2014 and its costs will be assumed by this University.

• DPX-0907 - Immunovaccine agreed to allow use of DPX-0907 in a Phase I/II study of breast and ovarian cancer patients at the Busto Arsizio Hospital in Italy. The study, which will be funded by Busto Arsizio, is expected to be initiated in 2014.

Six month chart :
Aeterna Zentaris Inc. (AEZS) (TSX: AEZ)  is a biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. Their pipeline includes Zoptarelin doxorubicin for Ovarian and prostate cancer, currently in Phase 11. Zoptarelin doxorubicin is a targeted cytotoxic peptide conjugate which is a hybrid molecule composed of a synthetic peptide carrier and a well-known cytotoxic agent, doxorubicin. The design of this product allows for the specific binding and selective uptake of the cytotoxic conjugate by the LHRH receptor-positive tumors. The binding of conjugate molecule zoptarelin doxorubicin to cancerous cells that express these receptors results in its accumulation in the malignant tissue. This binding is followed by internalization and retention of the cytotoxic drug, doxorubicin, in the cells. Therefore, since they target specific cells, cytotoxic conjugates are postulated to be more effective and have less side-effects than the respective non-conjugated/non-linked cytotoxic agents in inhibiting tumor growth.
Six month chart
TSX Life Sciences Snapshot
Life Sciences Markets at a Glance – YTD February 28, 2014

February   2014	TSX Venture (TSXV)	TSX	TSXV and TSX
Number of Issuers	69	39	108
QMV (C$)	2,153,038,500	63,319,048,526	65,472,087,027
New Listings	2	-	2
Equity Capital Raised (C$)	126,738,564	10,823,900	137,562,464
Number of Financings	18	2	20
Volume Traded	295,773,521	238,949,246	534,722,767
Value Traded (C$)	162,114,369	3,263,237,459	3,425,351,827
# of Trades	82,324	277,538	359,862

http://www.tmx.com/en/listings/sector_profiles/life_sciences.html
According to the TSX, nearly $3 billion of equity capital was raised by life sciences companies on TSX and TSXV in 2013.
About InvestorIdeas.com:
InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy and Latin American stocks.
Sign up for our free news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: QPT.V, a public company, has engaged Investorideas.com for public relations services for four thousand a month retainer fee.
More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Expand Brain Research Discoveries to Include Isolation of Glioblastoma Biomarker and Therapeutic Target

SAN DIEGO - March 19, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that researchers have isolated brainderived exosomes released into the bloodstream from aggressive brain tumors. Through the use of proprietary size exclusion/lectin/antibody-capture techniques, the Aethlon-ESI research team was able to identify, quantify, and characterize circulating Glioblastoma multiforme (GBM) exosomes, which hold promise as both a disease biomarker and therapeutic target as GBM exosomes are shed into the circulatory system to promote tumor growth and stimulate angiogenesis.

"Building on our proprietary method to identify, quantitate and characterize brain-derived exosomes, we now have the ability to detect this aggressive cancer early and aid in its treatment," stated ESI Chief Scientific Officer, Dr. Douglas Taylor.
Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. The Aethlon Hemopurifier® is a first in class medical device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that promote cancer progression and suppress the immune system of cancer patients. Aethlon is currently preparing to launch the first FDA approved clinical study of Hemopurifier® therapy in the United States. ESI was established by Aethlon to develop non-invasive exosome-based "liquid biopsies" that diagnose and monitor acute and chronic disease conditions.
GBM represents the most common, per capita costly and uniformly lethal primary brain tumor. GBM comprise 23% of primary brain tumors in the US and is the most commonly diagnosed brain tumor in adults aged 45-74 with men being more frequently diagnosed than women. The prognosis remains poor despite aggressive treatment modalities. Over the past decade, a median survival time of 12 months has only been marginally improved to 14.6 months as a result of advances in chemo/radiation and the use of molecularly targeted agents. Beyond being a candidate target for Hemopurifier® therapy, the discovery of circulating GBM-exosomes offers a potential new paradigm in GBM clinical management through a platform technology to predict tumor regression or progression.
"The ability to characterize disease specific exosomes in circulation will enable improved diagnosis to identify type and grade of these most challenging of brain tumors and may additionally help to advance novel treatment strategies," stated Dr. Cicek Gercel-Taylor, Clinical Research Director at ESI.
To date, there have been two critical barriers to successful GBM treatment. First, there currently is no method for evaluating the dynamic changes in GBM during therapy. Standard imaging approaches do not provide metrics of tumor-specific genetic/phenotypic changes and operative information is expensive, potentially morbid and limited by errors in topographic sampling. Second, clinicians, lacking tumor-specific parameters, are unable to effectively monitor responses to therapy over short time frames. These limitations are derived from the difficulty in obtaining repeated biopsies of tumor tissue, and the confounding effects on tumor MRI of necrosis, inflammation, surgical artifact and edema. Additionally, the appearance of GBM by current imaging techniques is not specific, since other lesions such as abscess, metastasis, and other entities may have a similar appearance. As a result, clinicians have not been able to adequately evaluate therapeutic agents designed to target GBM. The objective of the Aethlon-ESI team is to extend and improve GBM patient quality of life by resolving the clinical challenges of monitoring patient response to both established and candidate therapies.
Earlier this month, the Aethlon-ESI research team disclosed that it was also to isolate brain-specific biomarkers that could have implications in the diagnosis, monitoring and treatment of Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). The research studies provided evidence that exosomes can serve as a "liquid biopsy" to diagnose neurologic conditions. While exosomes from the central nervous system have previously been identified in the cerebrospinal fluid, the Aethlon-ESI study identified exosomes carrying brain-specific markers tau, beta-amyloid, glycoprotein A2B5 and S100B protein in the peripheral circulation of affected individuals. The discoveries provide a basis for an exosome-based platform that could enable the simultaneous identification of multiple brain specific markers that are transported across the blood-brain barrier and into the circulatory system.
CTE is a progressive degenerative disease, which at present can only be definitively diagnosed postmortem. CTE has been most commonly found at autopsy in former professional football players and has also been demonstrated to be prevalent in soldiers exposed to blast injury. The hallmark of CTE is the accumulation of tau, an abnormal protein that strangles brains cells in areas that control memory, emotions and other functions. TBI or repetitive brain trauma, including concussions and sub-concussive blows to the head contribute to the onset of CTE.
AD is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. Beta-amyloid plaques and neurofibrillary tangles have long been recognized as a common pathologic hallmark of AD. In 2010, it was estimated that 36 million people worldwide were living with AD.
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
About Exosome Sciences, Inc.
Exosome Sciences (ESI), a majority wholly owned subsidiary of Aethlon Medical, Inc., develops exosome-based solutions to improve identification and monitoring of acute and chronic conditions. Our candidate products are focused toward diagnostic advancements in the fields of oncology, infectious disease and brain injury. Exosomes represent an optimal diagnostic target as diseased or injured cells release these particles into body fluids such as urine, blood, saliva and cerebrospinal fluid where they can be accessed for analysis. Our exosome-based assays unlock the ability to identify proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive "liquid biopsies". Additional information can be found at www.ExosomeSciences.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: 2425 quarterly for annual news publishing only starting Feb 26th 2014
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar

Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) and Exosome Sciences Announce Brain Research Discoveries

SAN DIEGO - March 5, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer's Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.

The research studies provided evidence that exosomes can serve as a "liquid biopsy" to diagnose neurologic conditions. While exosomes from the central nervous system have previously been identified in the cerebrospinal fluid, the Aethlon-ESI study identified exosomes carrying brain-specific markers tau, beta-amyloid, glycoprotein A2B5 and S100B protein in the peripheral circulation of affected individuals. The discoveries provide a basis for an exosome-based platform that could enable the simultaneous identification of multiple brain specific markers that are transported across the blood-brain barrier and into the circulatory system.
CTE is a progressive degenerative disease, which at present can only be definitively diagnosed postmortem. CTE has been most commonly found at autopsy in former professional football players and has also been demonstrated to be prevalent in soldiers exposed to blast injury. The hallmark of CTE is the accumulation of tau, an abnormal protein that strangles brains cells in areas that control memory, emotions and other functions. TBI or repetitive brain trauma, including concussions and sub-concussive blows to the head contribute to the onset of CTE.
AD is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. Beta-amyloid plaques and neurofibrillary tangles have long been recognized as a common pathologic hallmark of AD. In 2010, it was estimated that 36 million people worldwide were living with AD.
"This advancement represents a new paradigm for brain injuries. In addition to providing definitive diagnosis, the proteomic and transcriptomic characterization of exosomes isolated specifically from the brain will provide a window into the molecular mechanisms underlying acute and chronic brain injuries," stated ESI Chief Scientific Officer, Dr. Douglas Taylor.
As a result of the discoveries, brain-derived exosomes can be specifically isolated and the protein and RNA cargoes identified. In studies of brain tissue, specific RNAs have been associated with development of neurological disorders, contributing to the onset and progression of brain injuries. Exosomal RNA and protein cargoes represent surrogates to brain biopsies and have utility as stable, clinically accessible biomarkers for brain injury detection, stratification of patients and therapeutic outcomes.
"With the exosome-based technologies developed by our group, we are at the verge of breakthroughs for the management and treatment of brain injuries and diseases that have been associated with disability and death," stated Dr. Cicek Gercel-Taylor, Clinical Research Director at ESI.
Circulating biomarkers have been proposed for the definitive diagnosis and monitoring treatment of brain injuries. The approach would enable diagnosing the condition, identifying processes that are difficult to image, monitoring responses to interventions, and predicting those who are at risk for long-term neurologic consequences. However, circulating biomarkers such as free protein and nucleic acids are extremely unstable in circulation, thus a high steady-state must be reached for detection, which is generally not observed except in severe cases. To circumvent these issues, exosome-associated biomarkers can be utilized as they are stable and detectable in the circulation.
"An exosome-based liquid biopsy that could identify the early onset of Alzheimer's disease or CTE in a living person may also unlock the ability to monitor disease progression and set the stage for new therapeutic advances, which could include Aethlon Medical therapeutic devices," stated Jim Joyce, CEO of Aethlon Medical and Executive Chairman at Exosome Sciences.
Therapeutic Application and Patent Application
The development of a therapeutic device that targets selective elimination of circulating beta-amyloid and tau is supported by the "peripheral sink" theory, which postulates that the reduction of these particles from systemic circulation promotes deplaquing from the brain. Thus, inhibiting the continued progression of neurodegenerative processes. Aethlon and ESI further disclosed the subsequent filing of a provisional patent entitled, "Brain Specific Exosome Based Diagnostics and Extracorporeal Therapies."
About Aethlon Medical, Inc.
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumorsecreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
About Exosome Sciences, Inc.
Exosome Sciences (ESI), a majority wholly owned subsidiary of Aethlon Medical, Inc., develops exosome-based solutions to improve identification and monitoring of acute and chronic conditions. Our candidate products are focused toward diagnostic advancements in the fields of oncology, infectious disease and brain injury. Exosomes represent an optimal diagnostic target as diseased or injured cells release these particles into body fluids such as urine, blood, saliva and cerebrospinal fluid where they can be accessed for analysis. Our exosome-based assays unlock the ability to identify proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive "liquid biopsies". Additional information can be found at www.ExosomeSciences.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's existing or future clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: 2425 quarterly for annual news publishing only starting Feb 26th 2014
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar